3 Biotech Stocks to Be Thankful for This Year Sun, 19 Nov 2017 16:43:00 +0000 If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised Fri, 10 Nov 2017 15:52:03 +0000 Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th Wed, 08 Nov 2017 12:00:00 +0000 Spectrum Pharmaceuticals, Inc. , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2017 London Healthcare Conference being held at the Waldorf Hilton in London.
Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update Thu, 02 Nov 2017 20:02:00 +0000 Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced today financial results for the three-month period ended September 30, 2017.
What’s Johnson & Johnson’s Valuation? Fri, 24 Nov 2017 18:30:56 +0000 As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.
Value-Adding Dividend Stocks To Buy Now Fri, 24 Nov 2017 13:02:22 +0000 A great investment for income investors with a long time horizon is in dividend-paying companies like Pfizer. Dividend stocks are a safe bet to increase your portfolio value as theyRead More...
Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Thu, 23 Nov 2017 14:00:14 +0000 The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
How Teva’s Generic Medicines Business Is Positioned after 3Q17 Wed, 22 Nov 2017 19:30:10 +0000 Teva's Generic Medicine segment generated 3Q17 revenues of $3.0 billion, which was ~8% higher YoY (year-over-year) but ~2% lower QoQ (quarter-over-quarter).
8 Bitcoin Stocks That You Won’t Lose Your Shirt Over Tue, 21 Nov 2017 16:59:45 +0000 Bitcoin may not have the trust of Wall Street institutions just yet, but millennials are all in. Blockchain Capital recently conducted a study of 2,000 millennials (aged 18-34) and asked them to make a theoretical choice between owning $1,000 in bonds or stocks and $1,000 in bitcoin. It seems millennials are laughing all the way to the decentralized blockchain.
November Pharma And Biotech Dividend Stocks To Look Out For Tue, 21 Nov 2017 13:03:25 +0000 Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...
Is Merck & Co. Inc. a Buy? Tue, 21 Nov 2017 11:12:00 +0000 Merck just might be poised for a rebound. But is the stock a smart long-term pick?
Understanding Abbott’s Alere Acquisition: What We Can Expect Fri, 24 Nov 2017 15:31:24 +0000 On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.
Inside Abbott’s Neuromodulation Business Growth Fri, 24 Nov 2017 14:01:31 +0000 Abbott's Medical Devices segment has products for rhythm management, heart failure, electrophysiology, structural heart diseases, neuromodulation, and more.
Should You Sell Abbott Laboratories (ABT) At This PE Ratio? Thu, 23 Nov 2017 16:01:04 +0000 Abbott Laboratories (NYSE:ABT) trades with a trailing P/E of 47.4x, which is higher than the industry average of 41.8x. Although some investors may jump to the conclusion that you shouldRead More...
Inside Abbott’s Growth: Understanding the Major Drivers Thu, 23 Nov 2017 12:34:23 +0000 Abbott Laboratories (ABT) registered sales of ~$6.8 billion for 3Q17, which represents YoY (year-over-year) sales growth of ~28.8% on a reported basis.
Abbott on the Street: Analyst Recommendations Wed, 22 Nov 2017 21:51:56 +0000 Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.
ETFs with exposure to Abbott Laboratories : November 20, 2017 Mon, 20 Nov 2017 16:22:26 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Abbott Laboratories Here are 5 ETFs with the largest exposure to ABT-US. Comparing the performance and risk of Abbott Laboratories with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Trade of the Day: Abbott Laboratories (ABT) Mon, 20 Nov 2017 13:57:00 +0000 To receive further updates on this Abbott Laboratories (NYSE:ABT) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.
How Johnson & Johnson’s Revenues Trended in 3Q17 Fri, 24 Nov 2017 21:35:11 +0000 Johnson & Johnson (JNJ) reported revenue growth of 10.3% to $19.7 billion during 3Q17 as compared to $17.8 billion during 3Q16.
Johnson & Johnson Reports Revenue Growth in 3Q17 Fri, 24 Nov 2017 20:05:19 +0000 Johnson & Johnson (JNJ) reported 10.3% growth in its revenues to $19.7 billion during 3Q17, as compared to revenues of $17.8 billion in 3Q16.
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU Fri, 24 Nov 2017 18:59:06 +0000 This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.
What’s Johnson & Johnson’s Valuation? Fri, 24 Nov 2017 18:30:56 +0000 As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.
How to Diversify Your Healthcare Investments Fri, 24 Nov 2017 14:37:00 +0000 In an all-too-often boom-or-bust sector like healthcare, it’s critical to make sure you’re diversifying your bets wisely.
As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen Mon, 27 Nov 2017 08:56:55 +0000 Britain pitched a new strategy for industry on Monday that sees greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union. Prime Minister Theresa May first flagged the plan in January, seven months after Britain voted to leave the European Union, adopting a hands-on approach to business that had largely been abandoned by her predecessors from the time of Margaret Thatcher in the 1980s. The government said it had secured major investments from global healthcare company MSD, known as Merck & Co in the United States, and German-based diagnostics company Qiagen ahead of the publication of the strategy.
UK launches plan for industry as Brexit looms, wins Merck investment Mon, 27 Nov 2017 00:01:00 +0000 The British government launched a new strategy for industry on Monday, aiming to intervene in key sectors to tackle weak productivity and bolster businesses to counter any new problems caused by Brexit. Prime Minister Theresa May first flagged the plan in January, seven months after Britain voted to leave the European Union, adopting a hands-on approach to business that had largely been abandoned by her predecessors from the time of Margaret Thatcher in the 1980s. Business Minister Greg Clark said Britain has some of the world's best universities and research institutions, as well as leading companies in sectors ranging from advanced manufacturing to financial services, life sciences and creative industries.
U.K. Seeks to Take Sting Out of Brexit With Industrial Strategy Mon, 27 Nov 2017 00:01:00 +0000 Business Secretary Greg Clark said reviving Britain’s flagging productivity lies at the heart of the industrial strategy he’ll unveil on Monday to help chart the future of Britain’s economy as the country ...
3 Companies Competing to Gain Lead in Ovarian Cancer Market Fri, 24 Nov 2017 16:24:04 +0000 Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
52-Week Company Lows Fri, 24 Nov 2017 15:44:46 +0000 Details the 52-week lows of the following companies: General Electric, Merck & Co., Schlumberger, Kinder Morgan, Williams Companies and Archer-Daniels Midland
Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Thu, 23 Nov 2017 14:00:14 +0000 The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.62 (median winner: 1.53)
Instit. Ownership: 72% (median winner: 63%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.